Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAZOLAMIDE vs DIAMOX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.
Carbonic anhydrase inhibitor; decreases aqueous humor production by inhibiting carbonic anhydrase in ciliary processes, leading to reduced intraocular pressure. Also inhibits carbonic anhydrase in renal tubules, causing bicarbonate diuresis and metabolic acidosis.
Edema due to congestive heart failure (adjunctive therapy),Drug-induced edema,Centrencephalic epilepsies (petit mal, unlocalized seizures),Chronic simple (open-angle) glaucoma,Secondary glaucoma,Preoperative lowering of intraocular pressure in acute angle-closure glaucoma,Altitude sickness (prevention and treatment),Off-label: Idiopathic intracranial hypertension, metabolic alkalosis, sleep apnea, bipolar disorder, cystinuria, hypokalemic periodic paralysis
Treatment of elevated intraocular pressure in open-angle glaucoma,Secondary glaucoma,Preoperative reduction of intraocular pressure in acute angle-closure glaucoma,Adjunctive treatment of edema due to congestive heart failure,Drug-induced edema,Centrencephalic epilepsies (petit mal, unlocalized seizures),Altitude sickness (acute mountain sickness) prophylaxis and treatment
250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.
250 mg orally every 6-8 hours for glaucoma; 250-375 mg orally once daily for altitude sickness; 5 mg/kg IV or IM every 6 hours for edema in congestive heart failure
Terminal half-life approximately 10–15 hours; prolonged in renal impairment (up to 30+ hours).
10-15 hours; prolonged to up to 24+ hours in renal impairment; clinical context: requires twice-daily dosing for continuous effect.
Primarily excreted unchanged in urine (70-100%). Minor metabolism via hydrolysis of acetyl group (possibly by plasma esterases) to acetazolamide, and glucuronide conjugation.
Metabolized primarily via hydrolysis to acetazolamide (active) and then further to inactive metabolites; minimal hepatic metabolism.
Renal: ~90% unchanged drug via tubular secretion and glomerular filtration; minor biliary/fecal (<2%).
Renal; 70-100% unchanged by tubular secretion and passive reabsorption; p H-dependent; alkaline urine increases elimination.
~70–90% bound primarily to carbonic anhydrase in erythrocytes and plasma proteins (albumin).
~90% bound, primarily to carbonic anhydrase in erythrocytes and plasma proteins (albumin).
0.2–0.3 L/kg; concentrates in tissues with high carbonic anhydrase content (RBCs, kidneys, eyes).
0.2 L/kg; distributes into total body water; concentrates in red blood cells, kidney, and eye.
Oral: ~100% (well absorbed); IV: 100%.
Oral: ~100% (well absorbed, but food may delay absorption).
Cr Cl 10-50 m L/min: administer every 12 hours; Cr Cl <10 m L/min: avoid use (ineffective).
GFR 10-50 m L/min: 250 mg every 12 hours; GFR <10 m L/min: avoid use
Child-Pugh class A: no adjustment; Child-Pugh class B-C: caution, reduce dose by 50% and monitor for encephalopathy.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
Children: 5-10 mg/kg/dose orally or IV every 8-12 hours; maximum 500 mg/dose.
Glaucoma: 8-15 mg/kg/day orally divided every 6-8 hours; Edema: 5 mg/kg IV or IM every 6 hours
Initiate at lowest effective dose (250 mg daily) due to increased risk of electrolyte disturbances and renal impairment.
Start at lowest dose (250 mg orally every 12 hours); monitor renal function and electrolytes due to increased risk of metabolic acidosis and hypokalemia
WARNING: Metabolically induced acidosis. Use with caution in patients with hepatic cirrhosis to avoid precipitation of hepatic encephalopathy. Not recommended for long-term use in patients with chronic noncongestive angle-closure glaucoma due to risk of increased intraocular pressure with lens displacement.
No FDA black box warning.
Sulfonamide hypersensitivity reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) - discontinue at first sign of rash,Metabolic acidosis - monitor electrolytes, use with caution in patients with respiratory acidosis or those at risk,Hepatic impairment - contraindicated in cirrhosis; may precipitate hepatic encephalopathy,Renal impairment (Cr Cl <10 m L/min) - ineffective and may cause metabolic acidosis,Hematologic reactions (agranulocytosis, aplastic anemia) - monitor CBC,Hypercalciuria and renal stone formation - ensure adequate hydration,Drowsiness, confusion, fatigue - impaired ability to drive/operate machinery,Use in pregnancy - potential risk; cross-sensitivity with sulfonamides
May cause metabolic acidosis; use caution in patients with pulmonary obstruction or emphysema.,Sulfonamide derivative; may cause hypersensitivity reactions including Stevens-Johnson syndrome.,Contraindicated in severe hepatic or renal dysfunction; may precipitate hepatic encephalopathy.,Monitor serum electrolytes and blood counts during prolonged therapy.,May impair mental alertness; caution when driving or operating machinery.
Hypersensitivity to acetazolamide or any sulfonamide derivative,Severe hepatic cirrhosis or hepatic impairment,Severe renal impairment (Cr Cl <10 m L/min) or anuria,Hyponatremia or hypokalemia,Adrenocortical insufficiency (Addison's disease),Long-term use in chronic noncongestive angle-closure glaucoma,Metabolic acidosis
Hypersensitivity to acetazolamide or any sulfonamide,Severe hepatic disease or cirrhosis,Severe renal impairment (Cr Cl <10 m L/min) or anuria,Hyponatremia or hypokalemia,Hyperchloremic acidosis,Adrenal insufficiency
Avoid high doses of vitamin C or cranberry juice as they may acidify urine and decrease drug effectiveness. Maintain adequate hydration; no specific food restrictions.
Avoid high-dose vitamin C (may increase risk of kidney stones). No other significant food interactions.
First trimester: Avoid; associated with increased risk of congenital malformations (limb defects, hypospadias). Second and third trimesters: Use only if clearly needed; may cause fetal metabolic acidosis, electrolyte disturbances, and growth retardation.
Diamox (acetazolamide) is a carbonic anhydrase inhibitor. Animal studies show teratogenic effects (limb malformations) at high doses, but human data limited. First trimester exposure may be associated with increased risk of congenital anomalies, particularly of the limbs and neural tube. Risk likely low but consider alternatives in first trimester. In second and third trimesters, no clear fetal toxicity but monitor for potential electrolyte imbalances and acidosis.
Excreted into breast milk (M/P ratio approximately 0.25). Not recommended due to risk of sulfonamide-related adverse effects (e.g., kernicterus in jaundiced infants, hemolytic anemia in G6PD deficiency).
Acetazolamide excreted into breast milk; M/P ratio approximately 0.25 for total acetazolamide, but for free drug may be higher. Milk levels low (about 10% of maternal serum). No reported adverse effects in infants; caution in neonates with renal or hepatic impairment, or those at risk for electrolyte disturbances.
No standard dose adjustment recommended; pharmacokinetics altered (increased Vd, decreased Cmax) but clinical significance uncertain. Monitor for metabolic acidosis and adjust if necessary.
Pregnancy-induced pharmacokinetic changes (increased renal clearance, expanded plasma volume) may require dose adjustments. No specific guidelines; monitor clinical response and serum electrolyte levels. Consider starting at lower doses (e.g., 250 mg daily) and titrate based on response and tolerability. In severe conditions (e.g., glaucoma), maintain effective dose but monitor closely for electrolyte disturbances and metabolic acidosis.
Acetazolamide is a carbonic anhydrase inhibitor used for glaucoma, altitude sickness, and as a diuretic. Monitor serum electrolytes (especially potassium and bicarbonate) due to metabolic acidosis risk. Avoid in severe hepatic or renal impairment. Can cause paresthesias, especially in hands and feet. Use with caution in patients with sulfonamide allergy as cross-reactivity is possible but rare.
DIAMOX (acetazolamide) is a carbonic anhydrase inhibitor used for glaucoma, altitude sickness, and edema. It can cause metabolic acidosis; monitor electrolytes. Avoid in severe hepatic or renal impairment. Use with caution in patients with sulfonamide allergy.
Take exactly as prescribed; do not stop suddenly.,May cause tingling or numbness in fingers, toes, or mouth; this is usually temporary.,Drink plenty of fluids unless otherwise directed; avoid excessive alcohol.,Report unusual fatigue, muscle cramps, or rapid breathing to your doctor.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,If used for altitude sickness, start 1-2 days before ascent and continue during climb.
Take exactly as prescribed; do not skip doses.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Drink plenty of fluids to prevent kidney stones.,Avoid alcohol as it may increase side effects.,Report any signs of allergic reaction (rash, hives, difficulty breathing) immediately.
"Bosutinib, a potent CYP3A4 inhibitor, can significantly increase the serum concentration of acetazolamide, a carbonic anhydrase inhibitor, by reducing its hepatic metabolism. This elevation may potentiate acetazolamide's adverse effects, including metabolic acidosis, electrolyte imbalances (e.g., hypokalemia), and paresthesias, especially in patients with renal impairment. Clinicians should monitor for signs of acetazolamide toxicity when coadministered with bosutinib."
"Acetazolamide, a carbonic anhydrase inhibitor, can cause metabolic acidosis and decrease renal tubular secretion of metformin, potentially increasing metformin plasma concentrations. This combination may elevate the risk of lactic acidosis, a rare but serious adverse effect of metformin. Additionally, acetazolamide-induced hypokalemia can exacerbate metformin-associated hyperlactatemia."
"Acetazolamide, a carbonic anhydrase inhibitor, increases urinary pH and promotes bicarbonate excretion, leading to metabolic alkalosis. This systemic alkalinization enhances renal tubular reabsorption of lithium, paradoxically decreasing lithium clearance and increasing serum lithium concentrations. Clinically, this can precipitate lithium toxicity, manifesting as nausea, tremor, ataxia, or confusion, particularly in patients on stable lithium regimens."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAZOLAMIDE vs DIAMOX, answered by our medical review team.
ACETAZOLAMIDE is a Carbonic Anhydrase Inhibitor that works by Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.. DIAMOX is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor; decreases aqueous humor production by inhibiting carbonic anhydrase in ciliary processes, leading to reduced intraocular pressure. Also inhibits carbonic anhydrase in renal tubules, causing bicarbonate diuresis and metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAZOLAMIDE and DIAMOX depend on the specific clinical indication. These are both Carbonic Anhydrase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAZOLAMIDE is: 250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.. The standard adult dose of DIAMOX is: 250 mg orally every 6-8 hours for glaucoma; 250-375 mg orally once daily for altitude sickness; 5 mg/kg IV or IM every 6 hours for edema in congestive heart failure. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAZOLAMIDE and DIAMOX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAZOLAMIDE is classified as Category C. First trimester: Avoid; associated with increased risk of congenital malformations (limb defects, hypospadias). Second and third trimesters: Use only if clearly needed; may cause f. DIAMOX is classified as Category C. Diamox (acetazolamide) is a carbonic anhydrase inhibitor. Animal studies show teratogenic effects (limb malformations) at high doses, but human data limited. First trimester exposu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.